Investigation of Asprosin a Novel Adipokine in Periodontitis

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between obesity, T2DM and periodontitis.we postulated that asprosin may be candidate for explaining the triangular relationship among obesity, T2DM, and periodontal disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Periodontitis Body Weight Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Mouth Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Periodontal Diseases Signs and Symptoms Stomatognathic Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Atatürk University Faculty of Dentistry

Erzurum, 25240, Turkey (Türkiye)

About this study

Periodontal disease is a chronic, multifactorial, and infectious disease caused by bacteria. It is characterized by the formation of an inflammatory response in the supporting bone and connective tissue against microbial dental plaque, and the nature of the resulting inflammatory response determines the course of periodontal disease. Type 2 Diabetes Mellitus (T2DM), obesity, and periodontal disease are closely related, presenting a triad association. Obesity is the crucial cause of T2DM and periodontitis is the sixth complication of diabetes. Asprosin circulates in the blood at nanomolar levels and is taken to the liver, where it activates the G protein-cAMP-PKA pathway, causing rapid glucose release into the circulation. Insulin-resistant humans and mice have been reported to have pathologically elevated plasma asprosin levels. It will be investigated whether asprosin, which we know to be effective on glucose metabolism, is affected by the periodontal condition.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All individuals were generally healthy,
non-smoking

Exclusion criteria

Pregnant or breastfeeding women
None had undergone periodontal therapy and/or antibiotic therapy in the past 6 months.
None has a contagious disease such as HIV or AIDS

Treatment and study plan

Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Diagnostic Test

Serum and saliva samples will be collected from both groups for biochemical analysis.

Primary outcomes

Asprosin Levels

Time frame: two weeks

Determination of asprosin levels by making biochemical analyzes from serum and saliva samples obtained

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Official study title

Serum and Saliva Asprosin Levels Are Associated With Periodontitis

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Jul 8, 2022
Registry last updated: Feb 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed